公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer | Rugo, Hope S; Cortes, Javier; Barrios, Carlos H; Cabrera, Paula; Xu, Binghe; CHIUN-SHENG HUANG ; Kim, Sung-Bae; Melisko, Michelle; Nanda, Rita; Pieńkowski, Tadeusz; Rapoport, Bernardo L; Schwab, Richard | Future oncology (London, England) | 5 | 1 | |
2022 | Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4 | Xu, Binghe; Hu, Xichun; Li, Wei; Sun, Tao; Shen, Kunwei; Wang, Shusen; Cheng, Ying; Zhang, Qingyuan; Cui, Shude; Tong, Zhongsheng; Geng, Cuizhi; Song, Erwei; CHIUN-SHENG HUANG ; et al., | European journal of cancer (Oxford, England : 1990) | 22 | 13 | |
2023 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial | Hurvitz, Sara A; Hegg, Roberto; Chung, Wei-Pang; Im, Seock-Ah; Jacot, William; Ganju, Vinod; Chiu, Joanne Wing Yan; Xu, Binghe; Hamilton, Erika; Madhusudan, Srinivasan; Iwata, Hiroji; Altintas, Sevilay; Henning, Jan-Willem; Curigliano, Giuseppe; Perez-Garcia, José Manuel; Kim, Sung-Bae; Petry, Vanessa; CHIUN-SHENG HUANG ; et al., | Lancet (London, England) | 142 | 77 | |